Difficulties of routine treatment are exaggeratedBMJ 1996; 312 doi: https://doi.org/10.1136/bmj.312.7022.52 (Published 06 January 1996) Cite this as: BMJ 1996;312:52
- Tom Marshall
- Registrar in public health medicine Northamptonshire Health Authority, Northampton NN1 5DN
EDITOR,—C M Sudlow and colleagues, and K G Sweeney and colleagues' commentary on their article, exaggerate the difficulties in acting on the research evidence on the use of anticoagulants in atrial fibrillation.1 They point to the risk of bleeding, the need for data on prevalence, and patients' preferences as areas of uncertainty.
Much of the evidence on the incidence of bleeding as a side effect of anticoagulant treatment derives from data recorded in the 1980s and earlier, since when the technology of monitoring has improved. Nevertheless, bleeds are a reason to consider stopping treatment, on the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial